Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?
Key takeaways
- Ricardo Pillai Sat, June 13, 2026 at 8:54 PM GMT+7 3 min read INDV Is INDV a good stock to buy?
- Indivior (INDV) is a specialty pharmaceutical company anchored by its SUBLOCADE franchise, which continues to drive accelerating fundamentals and cash generation.
- Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now? Ricardo Pillai Sat, June 13, 2026 at 8:54 PM GMT+7 3 min read INDV Is INDV a good stock to buy? We came across a bullish thesis on Indivior Pharmaceuticals, Inc. on The Mispricing Desk’s Substack. In this article, we will summarize the bulls’ thesis on INDV. Indivior Pharmaceuticals, Inc. s share was trading at $37.39 as of June 8th. INDV’s trailing and forward P/E were 19.30 and 12.27 respectively according to Yahoo Finance.
Indivior (INDV) is a specialty pharmaceutical company anchored by its SUBLOCADE franchise, which continues to drive accelerating fundamentals and cash generation. On April 30, 2026, Indivior raised full-year guidance to $1.215–$1.285 billion in net revenue and $620–$660 million in adjusted EBITDA after reporting Q1 revenue of $317 million, up 19% YoY, and adjusted EBITDA of $164 million, up 112%. SUBLOCADE remains the core growth engine with $232 million in revenue, up 32%, supported by expanding adoption and over 500,000 cumulative patients treated.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich